Personalis (NASDAQ:PSNL) Stock Price Up 13.5% – Time to Buy?

Personalis, Inc. (NASDAQ:PSNL)’s stock price was up 13.5% during mid-day trading on Monday . The stock traded as high as $6.88 and last traded at $7.2180. Approximately 332,325 shares changed hands during trading, a decline of 80% from the average daily volume of 1,650,960 shares. The stock had previously closed at $6.36.

Analysts Set New Price Targets

PSNL has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Morgan Stanley dropped their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Guggenheim raised their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC upped their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.00.

Personalis Stock Performance

The company has a market cap of $737.23 million, a P/E ratio of -6.90 and a beta of 1.96. The stock has a 50-day moving average of $6.56 and a two-hundred day moving average of $8.05.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, sell-side analysts forecast that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Trading of Personalis

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in shares of Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after acquiring an additional 33,044 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after acquiring an additional 101,706 shares during the period. Focus Partners Wealth purchased a new stake in Personalis during the 1st quarter valued at about $47,000. Finally, JPMorgan Chase & Co. grew its position in Personalis by 505.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after acquiring an additional 24,621 shares during the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.